OXFORD PHARMAGENESIS HOLDINGS LIMITED

1. OXFORD PHARMAGENESIS HOLDINGS LIMITED 2013-07-18 → present
2. MC499 LIMITED 2012-10-05 → 2013-07-18

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Shaw Gibbs (Audit) Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have a reasonable expectation that the group has adequate resources to continue in operational existence for the foreseeable future, thus they continue to adopt the going concern basis of accounting in preparing these financial statements.”

Group structure

1. OXFORD PHARMAGENESIS HOLDINGS LIMITED · parent
   1. Oxford PharmaGenesis AG 100% · Switzerland
   2. Oxford PharmaGenesis Inc 100% · USA
   3. Oxford PharmaGenesis Limited 100% · Oxfordshire
   4. Oxford PharmaGenesis Pty Ltd 100% · Australia

Significant events

• “The group achieved healthy revenue of £55.4m (2023: £60.6m) in the year ended 31 October 2024. This was achieved despite very challenging trading conditions in the first half of the year in the context of both the healthcare sector and wider global economy. The second half of the year saw a strong recovery and enabled the group to maintain a healthy operating profit of £7.5m (2023: £8.1m) and a marginally improved operating profit margin of 13.5% (2023: 13.4%).”
• “During the year, we established an Al Task Force to explore ways in which our delivery teams can develop and utilities Al to better serve our clients.”
• “The year saw an array of fundraising initiatives, including running and walking events, charity clothing drives, rowathons and donations to food hubs. The Charity Team also administered donations to charitable and community causes prioritised by the Board, as well as organising a local Wildlife Day.”
• “The group has launched our very first ESG report during the year and as part of our ESG strategy, we have recently committed to the Science Based Targets initiative (SBTi), including setting targets to reduce our carbon emissions.”
• “In October 2024, the company bought back 5,000 of its own shares for a consideration of £10,000,000.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

5

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -8.6%

  £60,610,424 → £55,393,300

• Cash

  -18.5%

  £9,177,311 → £7,477,023

• Net assets

  -21.6%

  £30,595,475 → £23,988,411

• Employees

  -5.5%

  525 → 496

• Operating profit

  -7.7%

  £8,112,524 → £7,490,863

• Profit before tax

  -6.4%

  £8,490,414 → £7,943,563

• Wages

  -8.4%

  £33,884,637 → £31,042,374

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers